MORGAN GOLDIZEN: Open Payments
NPI 1134890494 · ALTOONA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$710 in 41 payments from 14 companies in 2025. Trend: 2023 $580 · 2024 $699 · 2025 $710
Food & beverage: $710
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $147 |
| Lilly USA, LLC | 5 | $80 |
| GlaxoSmithKline, LLC. | 4 | $79 |
| Exact Sciences Corporation | 4 | $67 |
| AstraZeneca Pharmaceuticals LP | 3 | $60 |
| PFIZER INC. | 3 | $53 |
| Corcept Therapeutics | 3 | $50 |
| ABBVIE INC. | 2 | $43 |
| Amgen Inc. | 2 | $41 |
| Verona Pharma, Inc. | 1 | $24 |
Products named: Ozempic, MOUNJARO, TRELEGY ELLIPTA, Cologuard Collection Kit, AIRSUPRA, NURTEC ODT, Korlym, Wegovy.
Industry payments across PA — which companies pay providers there.
